In this study, plasma GM-CSF was a key marker (secondary to GM-CSF autoantibodies) for differentiating patients with aPAP from healthy volunteers and patients with COPD or asthma without aPAP. The gene discussed is CSF2; the disease is autoimmune pulmonary alveolar proteinosis.